All about COVID-19

Coronavirus | Russian vaccine generated strong immune response, says Lancet study

The report said the data showed that the vaccine was “safe, well tolerated, and does not cause serious adverse events in healthy adult volunteers”.   | Photo Credit: AP

The two-shot vaccine being developed by Russia’s Gamaleya Research Institute generated a strong immune response and didn’t produce serious adverse reactions in the 76 volunteers who were inoculated in a trial, according to results of a study reported online in The Lancet on Friday.

This is the first time that details of the early human studies — or Phase-1/2 trials, to check the vaccine’s safety and ability to generate an immune response — of the vaccines developed by Russia’s Gamaleya Research Institute have been reported in a peer-reviewed journal.

Two components

The vaccine consists of two components, a recombinant adenovirus type 26 (rAd26) vector and a recombinant adenovirus type 5 (rAd5) vector, both carrying the gene for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike glycoprotein (rAd26-S and rAd5-S).

Adenoviruses commonly affect humans and primates and have emerged as a sought-after platform to develop a vaccine against COVID-19. The ChAdOx1 vaccine candidate developed by Oxford University is based on a chimpanzee adenovirus vector platform and the Beijing Institute of Biotechnology and CanSino Biologics Inc. of China too are developing a vaccine on an adenovirus platform.

Also Read | Mass production of vaccine in 2021: Russia

Last month, Russian scientists said they had begun Phase-3 trials of their vaccine in 40,000 volunteers, results of which are likely to be publicly known by November.

In The Lancet, the scientists said the vaccines were given to the selected volunteers 21 days apart — the spacing meant to generate a boosted response — and checked for whether it induced protective antibodies as well as if it managed to stimulate the body’s cells into producing a class of cells that can destroy viral cells, a process known as a ‘humoral response.’ Both of these happened, the scientists claim, and no “serious adverse events” were reported.

However, between 28-50% of the volunteers reported pain at injection site, hyperthermia, headache, asthenia and muscle and joint pain. “Most adverse events were mild and no serious adverse events were detected,” the authors note.

Shahid Jameel, virologist and CEO, DBT-Welcome Trust, who read The Lancet study, told The Hindu that these were typical responses when vaccines were administered and based on what was reported, the vaccine candidates looked encouraging enough to be tested in large populations or a Phase-3 trial. “I would have liked to see a bigger number of volunteers in the Phase-2 component, at least in the hundreds, to capture the variety of population who are likely to get the vaccine. However the results look promising enough to progress to a Phase-3,” he said in a phone interview.

Also Read | Expert group will evaluate Russian, other vaccines: MEA

In comparison, the ChAdOx1 vaccine candidate has been tested in 1,100 volunteers as part of its Phase-2 trials.

“We are in close dialogue, agreements with certain companies in India. We appreciate that they didn’t ‘attack’ the vaccine but carefully sought to understand its mechanism of action. We are very grateful to India for the openness shown,” Kirill Dmitriev, CEO of Russian Direct Investment Fund, said in response to questions at a press briefing on Friday. The RDIF is in collaboration wit the Gamaleya Institute to develop and market the potential vaccine.

Experimental studies

So far, adenoviral vector vaccines have never been tested in commercial human vaccines except for a rabies vaccine but have been tested on people as part of experimental studies.

A potential problem with such vaccines is that adenoviruses being a common source of infection to human, the body’s immune system might fail to confer wide protection. Previous attempts at making adenovirus-based vaccines for HIV have been counter-productive. It is to overcome the challenges of pre-existing immunity, the Russian scientists say two doses of the vacccine were given.

Our code of editorial values

Related Topics
This article is closed for comments.
Please Email the Editor

Printable version | Dec 2, 2021 10:19:29 PM |

In This Package
The Hindu Explains | How is India preparing to roll out COVID-19 vaccines?
The Hindu Explains | Why was a COVID-19 vaccine dry run necessary, and how was it organised?
Coronavirus | Why people with prior infection still need COVID-19 vaccination
Explained | What we know about China-made vaccines
How infections among participants are a part of vaccine trials | The Hindu In Focus podcast
The Hindu Explains | What is emergency use authorisation for drugs and vaccines?
Coronavirus | How the new variant quickly accumulated 23 mutations
Coronavirus | New variant does not increase reinfection risk, disease severity, deaths
Coronavirus | N501Y mutation in SARS-CoV-2 virus causes increased infectivity in mice: researchers
The Hindu Explains | Are viruses expected to change form, and will vaccines protect against a mutating SARS-CoV-2?
Coronavirus | Is the first wave coming to an end in India?
Has India passed the COVID-19 peak? | The Hindu Parley podcast
Has India passed its COVID-19 peak, as a new government study claims? | The Hindu In Focus podcast
No evidence to suggest coronavirus cluster 5 variant found in minks increases virus transmissibility, disease severity
SARS-CoV-2 not the last virus to spark a pandemic, says expert
The Hindu Explains | Who are the top contenders in the race for a COVID-19 vaccine?
The vaccine networks India will rely on and the challenges ahead | The Hindu In Focus podcast
Study advances use of indomethacin for treatment of mild cases
How an asymptomatic player turned super-spreader
How close are we to getting a COVID-19 vaccine? | The Hindu In Focus podcast
WHO warns against pursuing herd immunity to stop coronavirus
Studies document in-flight transmission of coronavirus
Experimental study finds how coronavirus can spread while speaking
Can universal masking be a crude ‘vaccine’?
The Hindu Explains | Is COVID-19 setting off a bradykinin storm in the body?
Coronavirus | Lung damage in COVID-19 dead may shed light on ‘long COVID’: study
The Hindu Explains | What does herd immunity mean for COVID-19?
The Hindu Explains | What do we know about Russia’s COVID-19 vaccine candidate Sputnik V?
You are reading
Coronavirus | Russian vaccine generated strong immune response, says Lancet study
Watch | Is COVID-19 intensifying in rural India?
The Hindu Explains | Why is Phase-3 of COVID-19 vaccine trial complicated?
The Hindu Explains | What are the long-term effects of COVID-19?
The Hindu Explains | Are there re-infection fears around COVID-19?
Watch | COVID-19 and children
The Hindu Explains | Is SARS-CoV-2 a latent virus which can recur?
Watch | What is an immunity passport?
WHO says COVID-19 by far its worst global health emergency
CDC says revised guidance on coronavirus spread posted in error, removes it
Coronavirus | Plasma therapy may look promising in treating COVID-19, but it is no magic bullet
Coronavirus | Different kinds of SARS-CoV-2 exist in India but none more lethal than the other: Indian Academy of Sciences President
The Hindu Explains | Is airborne transmission of COVID-19 a risk?
Watch | What are serological surveys?
The Hindu Explains | Why is a psoriasis drug being used to treat COVID-19 patients?
Video: In conversation with Andrew Pollard, Director of Oxford Vaccine Group
Watch | All you need to know about pulse oximeters
Coronavirus | Why are only a fraction of cases tested?
Coronavirus | Vaccine was rapidly synthesised as novel coronavirus sequence was available, says virologist Gagandeep Kang
A step closer to developing a potent drug against novel coronavirus
Coronavirus | The importance of ‘contact tracing’
Coronavirus | Are diabetics more prone to COVID-19?
Private firms ready to test for COVID-19
Coronavirus | How does soap use help in tackling COVID-19?
Fight for the finite: On budgetary allocation for health
Coronavirus | A problematic testing strategy
Fighting COVID-19 together for a shared future
Scientists get ready to test rival COVID-19 pandemic vaccines in animals
Coronavirus | The cost of opacity
Watch | COVID-19: Masks and sanitisers are now essential commodities
A COVID-19 control plan made simple
Watch | Your COVID-19 queries answered
Coronavirus | How is India containing COVID-19?
Battle against COVID-19
Watch | COVID-19: Dos and don'ts from the Health Ministry
A COVID-19 response that is quick off the blocks
Watch | Why is COVID-19 not a pandemic yet?
Watch | Coronavirus: Can masks protect you?
Watch | How is India dealing with coronavirus?
WHO’s unexplained hesitancy
Watch | Bats and the novel coronavirus
Coronavirus | India shares two SARS-CoV-2 genome sequences
COVID-19 | We are in uncharted territory, says WHO
Explained | Why is COVID-19 not a pandemic yet?
New COVID-19 epidemic at ‘decisive point’: WHO chief
COVID-19 vaccine may be ready by 2022: SII
Explainer: How WHO names a new disease
WHO names deadly viral disease from China as 'COVID-19'
Explained | When can people transmit the novel coronavirus?
Analysis | For China’s Xi, the coronavirus challenge comes laden with economic costs and political risks
How bats harbour several viruses yet not get sick
WHO declares coronavirus outbreak a global emergency
Watch | What is Coronavirus?
What is the source of the new SARS-like disease reported in China?
Data | The wide, rapid spread of the novel coronavirus
Alarming spread: on novel coronavirus outbreak
Gaps in our knowledge of coronavirus origin need fulfilment: Study
A new virus emerges in China
Next Story